Abstract 1728P
Background
The prevalence of oncology survivors is increasing exponentially. More than half of them experience difficulty in returning to their pre-disease socio-familial role. Comprehensive Oncology Units are infrequent in our environment. In our center we have implemented this novel Unit in order to improve the quality of life of our cancer survivors during follow-up.
Methods
Prospective quasi-experimental study. From March 2022 to March 2023. A total of 232 patients were included in the Comprehensive Oncology Unit of the Juan Ramón Jiménez Hospital in Huelva. The aim of our study is to describe the psychosocial, nutritional and physical needs of cancer survivors during follow-up and the impact of the intervention on their quality of life.
Results
The median age of the patients was 53 years (33 - 78). Ninety-six percent were women. Ninety percent had been diagnosed with breast cancer, followed by 6 % CRC, 2 % other digestive tumors and 2 % gynecological tumors. 67.1% required assessment for nutrition, 62.9% for rehabilitation, 59.28% for psycho-oncology and 4.8% for social intervention. Of the patients who were evaluated by psycho-oncology, 50% improved their fear of recurrence with only 3 sessions. Regarding nutrition assessment, the median BMI in the population with BMI > 25kg/m2 was 30.7 Kg/m2 at baseline and 29.71 Kg/m2 (22.7 - 40) 6 months after nutrition intervention (p<0.001).
Conclusions
The results of our study reveal that there is a high demand of needs to be covered in cancer survivors beyond the purely clinical aspects that impact on their quality of life. Implementing a Comprehensive Oncology Unit could help to detect these needs and improve their healthy lifestyle habits as well as improve their quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Comprehensive Oncology Unit.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23